CARsgen Therapeutics Holdings Limited
2171.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$6.63B
Close$
$-0.69
105.9% downside
Current Fair Value
105.9% downsideOvervalued by 105.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $6.63 Billion |
|---|---|
| Enterprise Value | $5.36 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.18 |
| Beta | 0.26 |
| Outstanding Shares | 551,454,000 |
Return
| Return on Equity | -55.53% |
|---|---|
| Return on Assets | -38.70% |
| Return on Invested Capital | -43.37% |
Valuation & Multiples
| P/E Ratio | -61.69 |
|---|---|
| PEG | 527.92 |
| Price to Sales | - |
| Price to Book Ratio | 11.63 |
| Enterprise Value to Revenue | 24.27 |
| Enterprise Value to EBIT | -8.99 |
| Enterprise Value to Net Income | -9 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.12 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 18, 2026
EPS Estimate
$-0.22
Average shareholder expectationRevenue Estimate
$105.97 M
Average shareholder expectationNext Earnings Call
Expected Date
March 23, 2027
EPS Estimate
$-0.18
Average shareholder expectationRevenue Estimate
$248.02 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About CARsgen Therapeutics Holdings Limited
424 employees
CEO: Zonghai Li CARsgen Therapeutics Holdings Limited, a biopharmaceutical firm founded in Shanghai, China, in 2014, focuses on the discovery, development, and commercialization of advanced chimeric antigen receptor T (CAR-T) cell therapies. The company...